Monitor upcoming trial dates and further legal developments in the TESARO-AnaptysBio dispute, as a negative final ruling could threaten TESARO's rights to Jemperli, a drug with expanding commercial reach. For now, commercial operations and clinical development remain unaffected.
Price Chart
Executive Summary
GSK subsidiary TESARO received a procedural court win as the Delaware Chancery Court dismissed AnaptysBio's motion to counter its claim for anticipatory breach. The ruling does not resolve the core dispute over the dostarlimab (Jemperli) license, and TESARO continues to pursue its declaratory judgment claim. The litigation remains ongoing with no impact on Jemperli's commercial status or development pipeline.
Key Facts
- Delaware Chancery Court granted AnaptysBio's motion to dismiss TESARO's claim for anticipatory breach.
- The ruling is procedural and does not address the merits of the underlying contractual dispute over the dostarlimab license.
- TESARO's claim for declaratory judgment remains active, and GSK/TESARO intend to pursue it at trial.
- AnaptysBio had alleged TESARO failed to meet obligations under the 2014 license agreement and sought to revoke the dostarlimab license.
- Jemperli (dostarlimab) remains approved in over 35 countries for endometrial cancer, with ongoing trials in other indications including rectal, colon, and head and neck cancers.
Financial Impact
No immediate financial impact disclosed. The procedural ruling does not affect Jemperli's commercialization or development, which continues to show significant growth.
Risk Factors
- Risk that AnaptysBio may succeed in revoking the dostarlimab license at trial, jeopardizing future Jemperli revenue.
- Legal costs and management distraction from ongoing litigation.
- Potential disruption to Jemperli's development pipeline if licensing rights are invalidated.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-003940 |
| Document: 0001654954-26-003940-index-headers.html | 0001654954-26-003940 |
| Document: 0001654954-26-003940-index.html | 0001654954-26-003940 |
| Document: 0001654954-26-003940.txt | 0001654954-26-003940 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 10, 2026 19w ago | 6-K | $25.12 $25.25 | ▲ +0.52% | ▼ −1.62% | $26.12 (+3.98%) |
Jun 9, 2026 20w ago | 6-K | $24.66 $25.50 | ▲ +3.41% | ▲ +1.60% | $26.12 (+5.92%) |
Jun 9, 2026 20w ago | 6-K | $24.66 $25.50 | ▲ +3.41% | ▲ +1.60% | $26.12 (+5.92%) |
Jun 1, 2026 21w ago | 6-K | $24.25 $24.66 | ▲ +1.69% | ▲ +4.44% | $26.12 (+7.71%) |
Jun 1, 2026 21w ago | 6-K | $24.25 $24.66 | ▲ +1.69% | ▲ +4.44% | $26.12 (+7.71%) |
May 28, 2026 21w ago | 6-K | $24.58 $24.66 | ▲ +0.33% | ▲ +0.01% | $26.12 (+6.27%) |
May 27, 2026 21w ago | 6-K | $25.57 $23.94 | ▼ −6.37% | ▼ −7.58% | $26.12 (+2.15%) |
May 26, 2026 22w ago | 6-K | $25.50 $24.25 | ▼ −4.90% | ▼ −5.99% | $26.12 (+2.43%) |
May 26, 2026 22w ago | 6-K | $25.50 $24.25 | ▼ −4.90% | ▼ −5.99% | $26.12 (+2.43%) |
May 22, 2026 22w ago | 6-K | $26.00 $24.25 | ▼ −6.73% | ▼ −8.39% | $26.12 (+0.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers